Abbreviated Name

BBD Ref Set App: Marks (2015)

Lead Investigator

Marks, Jeffrey — Duke University Medical Center

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Godwin, Andrew K — University of Kansas Medical Center
• Marks, Jeffrey — Duke University Medical Center
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

No abstract availalbe.

Aims

We propose that two of the highest value markers based on published data (KI-67 and EZH2) will be performed by both Duke and Kansas.

Analytic Method

Our main BBD protocol argues that in order to be useful a biomarker should have a TPR/FPR ratio of at least 2.0, where TPR is the marker’s sensitivity and FPR is 1-specificity.

Comments

No comments available.

Outcome

This study is ongoing.

Secure Outcome

No secure outcome available.

Publications

• No publications available at this time for this protocol.

Biomarkers

• ALDH1A1
• CDKN2A (p16)
• CEACAM6
• EZH2
• GSTM1
• HYAL1
• MKI67
• MMP1
• PGR
• PTGS2
• TP53

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Start Date

Mar 31 2015

Estimated Finish Date

Aug 5 2015

Protocol ID

402

Protocol Type

Reference Set

Fields of Research

• Proteomics

Collaborative Group

Breast and Gynecologic Cancers Research Group

Cancer Types

• Malignant neoplasm of breast